home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Adama launches Armero, its first self-produced prothioconazole-based mixture - Leveraging in-house production of prothioconazole, opening up a $1 billion market


Beijing, China and Tel Aviv, Israel
December 16, 2019

ADAMA Ltd. (the “Company”) (SZSE 000553), today announced that it has successfully obtained regulatory approval in its first market, Paraguay, for ARMERO™ , its new dual-mode fungicide containing the active ingredients prothioconazole and mancozeb, benefiting from its new in-house production of prothioconazole, a broad-spectrum systemic fungicide. Following this important first registration of ARMERO™, the Company is progressing towards obtaining registrations in Brazil as the next and largest market for this product, to be followed by Europe and other countries globally for additional product concepts containing prothioconazole.

Complementing ADAMA’s flagship CRONNOS®, the triple-action fungicide for Asian soybean rust launched in 2018, ARMERO™ is the first product that ADAMA will introduce in the market with its in-house production of prothioconazole. A mixture of two active ingredients, ARMERO™, ensures a combination of different modes of action including a multisite protectant to combat resistance, and is ideal as a first application of the spray program to control Asian soybean rust. Its innovative liquid formulation, with the Company's proprietary T.O.V technology, prevents spray nozzles from clogging, creating simplicity for farmers.

ARMERO™ is a key product in controlling Asian soybean rust, a highly impactful disease which causes significant crop damage and yield loss of up to 90%, and is expected to be an important growth driver for ADAMA in the future. The market size of the prothioconazole active ingredient is approximately $800 million and is expected to reach over a billion dollars by 2025.

ADAMA is expanding its production capabilities and resources to meet the expected high demand for prothioconazole. The Company is in the process of aligning with industry partners , aiming to become a major supplier of this key active ingredient.

“This new in-house production of prothioconazole enables us to leverage our competitive, backward-integrated cost position while strategically aligning with our global distribution channels to expand sales of distinctive mixture and formulation products, creating building blocks for our future offering,” said Carlos Danilowicz, VP, Latin America.



More news from: Adama


Website: http://www.adama.com/en/

Published: December 18, 2019

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section


Copyright @ 1992-2025 SeedQuest - All rights reserved